Figures & data
Figure 1 (A–E) Clinical manifestations of hereditary leiomyomatosis and renal cell carcinoma (HLRCC): leiomyomas.
![Figure 1 (A–E) Clinical manifestations of hereditary leiomyomatosis and renal cell carcinoma (HLRCC): leiomyomas.](/cms/asset/7700ae0a-00e0-4c1a-926d-896d6c41e3c7/dnrd_a_42097_f0001_c.jpg)
Figure 2 (A–E) Clinical manifestations of hereditary leiomyomatosis and renal cell carcinoma (HLRCC): renal tumors.
Abbreviation: RCC, renal cell carcinoma.
![Figure 2 (A–E) Clinical manifestations of hereditary leiomyomatosis and renal cell carcinoma (HLRCC): renal tumors.](/cms/asset/2dfcda66-e66a-49e4-a935-699d016eb50d/dnrd_a_42097_f0002_c.jpg)
Table 1 Diagnostic criteria for hereditary leiomyomatosis and renal cell carcinoma (HLRCC)
Figure 3 Potential biochemical pathways deregulated as a consequence of FH inactivation.
Abbreviations: LDHA, lactate dehydrogenase A; CoA, coenzyme A; αKG, α-ketoglutarate; FH, fumarate hydratase; GLUT1, glucose transporter 1; KEAP1, kelch-like ECH-associated protein 1; CUL3, cullin 3; HIF-1α, hypoxia-inducible factor 1 alpha; VEGF, vascular endothelial growth factor; PDH, pyruvate dehydrogenase; PDK1, pyruvate dehydrogenase kinase 1.
![Figure 3 Potential biochemical pathways deregulated as a consequence of FH inactivation.](/cms/asset/e121ebe8-a5e7-46c2-86a3-a5c9be0c6aff/dnrd_a_42097_f0003_c.jpg)